Leading Biosciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
Phase 2
Withdrawn
- Conditions
- Coronavirus Disease 2019Covid19COVID-19 PneumoniaCOVID-19
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Leading BioSciences, Inc
- Registration Number
- NCT04390217
Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148
- First Posted Date
- 2014-12-16
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Leading BioSciences, Inc
- Target Recruit Count
- 8
- Registration Number
- NCT02317549
- Locations
- 🇺🇸
Providence Hospital, Mobile, Alabama, United States
🇺🇸Community Regional Medical Center, Fresno, Fresno, California, United States
🇺🇸Long Beach Memorial Medical Center, Long Beach, California, United States
News
No news found